

Forest Laboratories

[View the current Forest Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/4182-Forest+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/4182-Forest+Laboratories.html>)

Contact Details:

909 Third Avenue

New York

NY

10022-4731

United States of America

Tel: 212 421 7850

Fax:

Email: InvestorRelations@frx.com

Forest Laboratories develops, manufactures and sells both branded and generic forms of ethical products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.

Forest products are marketed principally in the United States and western and eastern Europe. Marketing is conducted by Forest and through independent distributors.

In the United States, Forest's ethical specialty products are marketed directly by the Company's Forest Pharmaceuticals, Forest Therapeutics, and Forest Specialty Sales salesforces. The Company's generic products are marketed directly by its Inwood Laboratories, Inc. subsidiary.

In the United Kingdom, Ireland and certain export markets, Forest products are marketed directly by the Company's subsidiaries, Pharmax Limited and the Tosara Group. Pharmax is a U.K. manufacturer and marketer of a range of specialty pharmaceuticals, including products manufactured by Forest and Tosara.

Recent Publications by Forest Laboratories:



- [Effect of position isomerism on the formation and physicochemical properties of pharmaceutical co-crystals.](#)
*The effect of position isomerism on the co-crystals formation and...*9th June, 2009
Forest Laboratories, Inc., 49 Mall Drive, Commack, New York 11725.- J Pharm Sci. 2009 Jun 5. ([DOI](#) [Direct Link](#))
- [Modified-release solid formulations for colonic delivery.](#)
*Solid formulations intended for targeted drug release into the lower...*27th March, 2009
Department of Formulation, Pharmaceutical Research & Development, Forest- Recent Pat Drug Deliv Formul. 2007;1(1):53-63.
- [Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized](#)

[anxiety disorder.](#)

Generalized anxiety disorder (GAD) is a highly prevalent and disabling... 28th February, 2009
Forest Laboratories, Harborside Financial Center, Jersey City, New Jersey,- *Depress Anxiety.*
2008;25(10):854-61. ([DOI Direct Link](#))

- [Drug Safety and Pharmacovigilance--second annual marcus evans conference.](#)
Generalized anxiety disorder (GAD) is a highly prevalent and disabling... 11th July, 2007
Forest Laboratories UK Ltd, Bourne Road, Bexley, Kent, DA5 1NX, UK.- *IDrugs.* 2007 Mar;10(3):165-8.
- [Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.](#)
Cancer chemotherapeutic prodrugs, such as the oxazaphosphorines... 28th April, 2006
Forest Research Institute, A Division of Forest Laboratories, Inc.,- *Toxicol In Vitro.* 2006 Mar;20(2):176-86. Epub 2005 Nov 15. ([DOI Direct Link](#))
- [Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.](#)
BACKGROUND: The high prevalence rates of both Alzheimer's disease (AD) and... 2nd February, 2006
Forest Research Institute, Forest Laboratories, Inc., Jersey City, New- *Clin Ther.* 2005 Oct;27(10):1596-606. ([DOI Direct Link](#))
- [Effects of formulation variables and characterization of guaifenesin wax microspheres for controlled release.](#)
Sustained-release wax microspheres of guaifenesin, a highly water-soluble... 15th July, 2005
Forest Laboratories Inc, Commack, New York, USA.- *Pharm Dev Technol.* 2005;10(1):71-83. ([DOI Direct Link](#))
- [Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.](#)
BACKGROUND: As part of ongoing studies to evaluate the analgesic efficacy... 29th April, 2005
Pharmacokinetic Properties Department, Forest Laboratories Inc.,- *Clin Ther.* 2004 Dec;26(12):2015-25. ([DOI Direct Link](#))
- [Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid.](#)
The objective of this study was to produce, by spray freezing into liquid... 7th January, 2005
Pharmaceutical Research and Development, Forest Laboratories, Inc.,- *Drug Dev Ind Pharm.* 2004 Aug;30(7):695-704. ([DOI Direct Link](#))
- [Microencapsulation of a hydrophilic drug into a hydrophobic matrix using a salting-out procedure. I: Development and optimization of the process using factorial design.](#)
The congealable disperse phase method for preparing sustained release... 15th September, 2004
Forest Laboratories, Inc., 330 Propsect Street, Inwood, NY 11096, USA.- *J Microencapsul.* 2004 Mar;21(2):125-35. ([DOI Direct Link](#))
- [Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine.](#)
3'-Azido-2', 3'-dideoxyuridine (AZDU, AzddU, CS-87) has been shown to have... 31st August, 2004
Forest Laboratories, Inc., Jersey City, NJ, USA.- *Antivir Chem Chemother.* 2003 Sep;14(5):263-70.
- [Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.](#)
Poor water solubility is an industry wide issue, especially for... 10th July, 2004
Pharmaceutical Research and Development, Forest Laboratories, Inc.,- *Drug Dev Ind Pharm.* 2004 Mar;30(3):233-45. ([DOI Direct Link](#))
- [An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.](#)
BACKGROUND: Depression often coexists with a number of disease states, and... 30th August, 2003
Forest Laboratories, Inc., New York, New York, USA.- *Clin Ther.* 2003 Apr;25(4):1200-10.
- [Multiple-dose proportionality study of flunisolide hydrofluoroalkane.](#)
The hydrofluoroalkane (HFA) formulation of the inhaled corticosteroid... 13th March, 2003
Department of Pharmacokinetics, Forest Laboratories, Inc., Harborside- *Allergy Asthma Proc.* 2002 Sep-Oct;23(5):311-8.

Press Releases on Forest Laboratories:

Reportlinker Adds Hand Sanitizers - US Market Trends	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Hand Sanitizers - US Market Trends http://www.reportlinker.com/p0164260
Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients	23rd November, 2009	Proteon Therapeutics, Inc.	WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing
Four Senior Executives Join Orexigen(R) Therapeutics Management Team	23rd November, 2009	Orexigen Therapeutics, Inc.	SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director	23rd November, 2009	Immune Design Corp.	SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology
Counselors Address Mental-Health Crisis in Developing Countries	20th November, 2009	Wake Forest University	WINSTON-SALEM, N.C., Nov. 20 /PRNewswire-USNewswire/ -- Worldwide, more than 450 million people live with unmet mental health care needs. Wake Forest University Counseling Professor Donna Henderson co

BioNews Results for Forest Laboratories



- [Nycomed reports continued satisfactory performance in the third quarter 2009](#)
World Pharma News: Nov 15 2009 12:42AM Matching: forest laboratories
- [United Therapeutics a good takeover candidate, analyst says](#)
Gazette.net: Nov 14 2009 11:14AM Matching: forest laboratories
- [Nycomed reports continued satisfactory performance in the third quarter 2009](#)
Pharma Live: Nov 13 2009 3:52AM Matching: forest laboratories
- [Takeover likely for United, analyst says](#)
Gazette.net: Nov 13 2009 5:43PM Matching: forest laboratories
- [Nycomed reports continued satisfactory performance in the third quarter 2009](#)
Therapeutics Daily: Nov 12 2009 1:48PM Matching: forest laboratories

- [Forest Reports Settlement With DOJ](#)
Pharma Live: Nov 12 2009 10:53AM Matching: forest laboratories
- [Nycomed confident it can survive pantoprazole patent expiries](#)
Pharma Times: Nov 12 2009 12:31PM Matching: forest laboratories
- [Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research](#)
Earthtimes.org: Nov 12 2009 7:17AM Matching: forest laboratories
- [Astellas Enters Asian Licensing Agreement for Ironwoods Phase III IBS Therapy with \\$30M](#)
Genetic Engineering News: Nov 11 2009 6:02PM Matching: forest laboratories
- [Ironwood Licenses Bowel Drug Linaclotide to Astellas for \\$75M](#)
Therapeutics Daily: Nov 11 2009 2:51AM Matching: forest laboratories
- [Justice eyes marketing at J&J, Forest](#)
FiercePharma: Nov 10 2009 5:31PM Matching: forest laboratories
- [Ironwood lands \\$75M Asian deal for linaclotide](#)
FierceBiotech: Nov 10 2009 5:11PM Matching: forest laboratories
- [Cypress Bioscience takes bigger loss as costs rise](#)
AP via Yahoo!: Nov 9 2009 8:09PM Matching: forest laboratories
- [Cypress Bioscience says 3rd - quarter loss grew due to costs connected to launch of Savella](#)
Canadian Business Magazine: Nov 9 2009 8:02PM Matching: forest laboratories
- [Cypress Bioscience takes bigger loss as costs rise](#)
Yahoo! Canada: Nov 9 2009 7:53PM Matching: forest laboratories

Forest Laboratories Clinical Trials:



- [Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-Release \(ER\) for Hypertension](#)

Forest Laboratories Patents:



- 7569605- [Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion](#)
- 4357469- [Carrier base material for prolonged release therapeutic compositions](#)
- 4369172- [Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose](#)
- 4389393- [Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose](#)
- 4482534- [Nitroglycerin preparations](#)
- 4533540- [Nitroglycerin-containing polymeric matrix for sustained release on topical application](#)
- 4540566- [Prolonged release drug dosage forms based on modified low viscosity grade](#)

[hydroxypropylmethylcellulose](#)

- 4795327- [Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants](#)
- 4849229- [Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants](#)
- 4983398- [Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates](#)
- 5527822- [Method of treatment of traumatic brain injury](#)
- 7456224- [Method for treating autism](#)
- 7501438- [Pyridoimidazole derivatives](#)
- 7511150- [Synthesis of heterocyclic compounds](#)
- 7563797- [Substituted imidazo\(1,2-A\)pyrimidines and imidazo\(1,2-A\) pyridines as cannabinoid receptor ligands](#)
- 4226849- [Sustained release therapeutic compositions](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

